



ACIP COVID-19 Vaccines Work Group

Robert Schechter, MD
COVID-19 ACIP Work Group Chair

Advisory Committee on Immunization Practices Meeting
October 23, 2024

Current 2024–2025 COVID-19 vaccine recommendations

- To protect against COVID-19 disease, caused by SARS-CoV-2, ACIP recommended at its June 2024 meeting the 2024–2025 COVID-19 vaccines, as authorized or approved by FDA:
 - Moderna COVID-19 vaccine in persons ≥ 6 months
 - Pfizer-BioNTech COVID-19 vaccine in persons ≥ 6 months
 - Novavax COVID-19 vaccine in persons ≥ 12 years*
- Everyone aged 5 years and older should get 1 dose of a 2024–2025 COVID-19 vaccine
- Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of 2024–2025 COVID-19 vaccine
- People who are moderately or severely immune compromised may receive additional doses of 2024–2025 COVID-19 vaccines under shared clinical decision making
- No recommendation for additional doses of 2024–2025 COVID-19 vaccine for older adults

*People who are previously unvaccinated for COVID-19 and are receiving Novavax should complete a 2-dose initial series

Current 2024–2025 COVID-19 vaccine recommendations

- To protect against COVID-19 disease, caused by SARS-CoV-2, ACIP recommended at its June 2024 meeting the 2024–2025 COVID-19 vaccines, as authorized or approved by FDA:
 - Moderna COVID-19 vaccine in persons ≥ 6 months
 - Pfizer-BioNTech COVID-19 vaccine in persons ≥ 6 months
 - Novavax COVID-19 vaccine in persons ≥ 12 years*
- Everyone aged 5 years and older should get 1 dose of a 2024–2025 COVID-19 vaccine
- Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of 2024–2025 COVID-19 vaccine
- People who are moderately or severely immune compromised may receive additional doses of 2024–2025 COVID-19 vaccines under shared clinical decision making
- No recommendation for additional doses of 2024–2025 COVID-19 vaccine for older adults

*People who are previously unvaccinated for COVID-19 and are receiving Novavax should complete a 2-dose initial series

ACIP COVID-19 Work Group Meeting Review

July – October 2024

- Seasonality of SARS-CoV-2
- Epidemiology of COVID-19 in older adults and persons with immunocompromise
- SARS-CoV-2 variant updates
- Vaccine safety update

Regarding additional doses of COVID-19 vaccine:

- Vaccine effectiveness
- Uptake and intent survey data
- Economic analyses
- Implementation

Agenda: October 23, 2024

Introduction

Dr. Robert Schechter (ACIP, WG Chair)

COVID-19 vaccine uptake and implementation

Dr. Georgina Peacock (CDC/NCIRD)

COVID-19 epidemiology

Dr. Christopher Taylor (CDC/NCIRD)

COVID-19 vaccine effectiveness

Dr. Ruth Link-Gelles (CDC/NCIRD)

**Economic analysis of an additional dose of the
2024-2025 COVID-19 vaccine**

Dr. Lisa Prosser (University of Michigan)

Evidence to Recommendations

Ms. Lauren Roper (CDC/NCIRD)

Clinical considerations

Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)

Vote

Ms. Lauren Roper (CDC/NCIRD)

Vote language

In addition to previously recommended 2024–2025 vaccination:

- ACIP recommends a **second dose*** of 2024–2025 COVID-19 vaccine for adults ages ≥ 65 years
- ACIP recommends a **second dose**** of 2024–2025 COVID-19 vaccine for people ages 6 months–64 years who are moderately or severely immunocompromised
- ACIP recommends **additional doses (i.e., 3 or more doses)** of 2024–2025 COVID-19 vaccine for people ages ≥ 6 months who are moderately or severely immunocompromised under *shared clinical decision making*

*If previously unvaccinated and receiving Novavax, 2 doses are recommended as initial vaccination series followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine 6 months (minimum interval 2 months) after second dose.

**If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024–2025 vaccine are recommended, and depending on vaccination history more may be needed. This additional 2024–2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of initial vaccination series.

Recent COVID-NET Reports Describe Low Immunization Rates in Hospitalized, High-Risk Populations

- During October 2023–April 2024, adults aged ≥ 65 years accounted for 70% of all COVID-19–associated hospitalizations among adults.
 - Most hospitalized adults had multiple underlying medical conditions.
 - 12% had received the recommended COVID-19 2023–2024 formula vaccine.
- During October 2022–April 2024, COVID-19–associated hospitalization rates in infants aged < 6 months were similar to those in adults aged 65–74 years.
 - The percentage of hospitalized infants whose mothers had been vaccinated during pregnancy was 18% during October 2022–September 2023 and decreased to $< 5\%$ during October 2023–April 2024.

Work Group members

ACIP members

- Robert Schechter (chair)
- Noel Brewer
- Oliver Brooks
- George Kuchel
- Keipp Talbot

Ex-officio/government members

- BARDA: Christine Oshansky
- CDC: Alan Lam
- FDA: Adam Spanier, Rachel Zhang
- IHS: Uzo Chukwuma
- NIH: Chris Roberts

CDC co-Leads

- Lakshmi Panagiotakopoulos
- Lauren Roper

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Naima Joseph (primary),
Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Heather Roth
- AMA: Sandra Fryhofer
- ANA: Ruth Francis
- APhA: Richard Dang
- ASTHO: Marcus Plescia
- CSTE: Paul Cieslak, Christine Hahn
- IDSA: James McAuley

Liaisons, cont’d

- NACCHO: Matt Zahn
- NACI: Eva Wong (primary),
Matthew Tunis (alternate)
- NFID: Robert Hopkins (primary),
Bill Schaffner (alternate)
- SHEA: Preeti Mehrotra (primary),
Marci Drees (alternate)

Consultants

- Ed Belongia
- Dayna Matthew
- Hank Bernstein
- Jennifer Nelson
- Matthew Daley
- Stanley Perlman
- Kathy Edwards
- Peter Szilagyi
- Lisa Jackson

CDC participants

- Amadea Britton
- Mary Chamberland
- Fatimah Dawood
- Jonathan Duffy
- Katherine Fleming-Dutra
- Kristen Folsom
- Julianne Gee
- Monica Godfrey
- Susan Goldstein
- Lisa Grohskopf
- Aron Hall
- Elisha Hall
- Demorah Hayes
- Suzanne Heitfeld
- Rita Helfand
- Michele Hlavsa
- Jefferson Jones
- Ruth Link-Gelles
- Jessica MacNeil
- Josephine Mak
- Seth Abram Meador
- Michael Melgar
- Sarah Meyer
- Noelle-Angelique Molinari
- Danielle Moulia
- Ismael Ortega-Sanchez
- Manisha Patel
- Amanda Payne
- Jamison Pike
- Hannah Rosenblum
- Sierra Scarbrough
- John Su
- Diya Surie
- Natalie Thornburg
- David Wentworth
- Melinda Wharton
- Trang Wisard
- JoEllen Wolicki

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 [cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

